Cas:64506-22-5 5-tert-butyl-2-[2-[4-[2-(5-tert-butyl-1,3-benzoxazol-2-yl)ethenyl]phenyl]ethenyl]-1,3-benzoxazole manufacturer & supplier

Chemical Name:5-tert-butyl-2-[2-[4-[2-(5-tert-butyl-1,3-benzoxazol-2-yl)ethenyl]phenyl]ethenyl]-1,3-benzoxazole

CAS.NO:64506-22-5

Synonyms:5-tert-butyl-2-(2-(4-(2-(5-tert-butylbenzoxazol-2-yl)vinyl)phenyl)vinyl)benzoxazole

Molecular Formula:C₃₂H₃₂N₂O₂

Molecular Weight:476.60900

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:52.06000

Exact Mass:476.24600

LogP:8.90480

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 5-tert-butyl-2-(2-(4-(2-(5-tert-butylbenzoxazol-2-yl)vinyl)phenyl)vinyl)benzoxazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-tert-butyl-2-(2-(4-(2-(5-tert-butylbenzoxazol-2-yl)vinyl)phenyl)vinyl)benzoxazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-tert-butyl-2-(2-(4-(2-(5-tert-butylbenzoxazol-2-yl)vinyl)phenyl)vinyl)benzoxazole Use and application,5-tert-butyl-2-(2-(4-(2-(5-tert-butylbenzoxazol-2-yl)vinyl)phenyl)vinyl)benzoxazole technical grade,usp/ep/jp grade.

Related News: “The most important thing to be considered while determining a CDMO competency is their technical knowledge along with adequate expertise to accomplish the drug development till commercial scaling. di(adamant-1-yl) 2-(N,N-dimethylamino)ethyl phosphite manufacturers It is always advisable for companies to start the clinical study responsibilities early on to combat unforeseen challenges that require more time. 2-Methyl-1,4-dihydro-indeno[1,2-b]pyrrole suppliers “The jury was careful and awarded us what we’d asked for down to the penny,” Plexxikon’s lawyer Daralyn Durie told Bloomberg after the verdict came down. phenylmethyl 2,7,7-trimethyl-5-oxo-4-phenyl-1,4,6,7,8-pentahydroquinoline-3-carboxylate vendor & factory But when it came to deciding on whether Americans with compromised immune systems should get an extra dose of any COVID-19 vaccine, the CDC said it would need to wait for the FDA to give its regulatory thumbs up first. That could come either through amending its emergency use nods or awarding full approvals.,“The most important thing to be considered while determining a CDMO competency is their technical knowledge along with adequate expertise to accomplish the drug development till commercial scaling.